Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases.

Advances in radiation oncology·2026

Same author

Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis.

Neuro-oncology advances·2026

Same author

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

Cancer research communications·2025

Same author

Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis.

Nature·2025

Same author

Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.

The Journal of experimental medicine·2025

Same author

Correction: Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation.

The Journal of experimental medicine·2025

Search research articles

Related Experiment Video

Updated: Sep 20, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Oligometastatic Breast Cancer.

Jonathan B Strauss¹, Steven J Chmura²

¹Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611.

Seminars in Radiation Oncology

|June 10, 2022

Summary

Oligometastatic breast cancer, defined by 1-5 metastases, may benefit from high-intensity focused radiation therapy (HIFRT). The SABR-COMET trial showed HIFRT improved survival compared to standard care in these patients.

More Related Videos

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

Related Experiment Videos

Last Updated: Sep 20, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

Area of Science:

Oncology
Radiation Oncology
Medical Oncology

Background:

Oligometastatic breast cancer (1-5 metastases) is an intermediate stage with a distinct molecular profile and better prognosis than widely metastatic disease.
This limited metastatic state may be amenable to aggressive, ablative therapies targeting known disease sites.
Current selection criteria include a disease-free interval >2 years, limited metastases, and fewer involved organs.

Purpose of the Study:

To evaluate the efficacy of high-intensity, image-guided, robotic radiotherapy (HIGRT) in patients with oligometastatic breast cancer.
To compare survival outcomes between HIGRT and standard of care in this patient population.

Main Methods:

The phase II SABR-COMET trial enrolled patients with oligometastatic disease across multiple histologies.
Patients were randomized to receive either HIGRT or standard of care treatment.
Outcomes were assessed based on survival advantage.

Main Results:

The study found a notable survival advantage for patients treated with HIGRT compared to the standard of care group.
HIGRT demonstrated potential as an effective ablative therapy for oligometastatic disease.

Conclusions:

HIGRT shows promise for improving survival in oligometastatic breast cancer.
Ongoing trials continue to explore HIGRT's role, with future research aiming to refine patient selection using molecular signatures and clinical criteria.